Yahoo Web Search

Search results

  1. May 7, 2024 · Novartis Philippines. Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

    • About

      The ability to attract, grow and keep talented people is...

    • Novartis in Philippines

      In 2023, the full Novartis portfolio of medicines reached 1...

    • Healthcare Professionals

      Healthcare Professionals Resources for the Philippines...

    • News

      Products Novartis Pipeline Adverse Event Reporting Novartis...

    • Contact

      Zuellig Pharma Corporation (ZPC) is the exclusive...

    • Patient Resources

      Unblocked Heart Health Take control of your health and...

    • ESG

      Products Novartis Pipeline Adverse Event Reporting Novartis...

    • Stories

      Asia Pacific Patient Innovation Summit: Philippines Outcome...

  2. In 2023, the full Novartis portfolio of medicines reached 1 million Filipino patients. Filipino patients who took Novartis medicines gained a total of 7,355 quality-adjusted life-year (QALYs). QALY is a generic measure of disease burden, including both the quality and the quantity of life lived.

  3. www.novartis.com › about › productsProducts | Novartis

    Discover the diverse and innovative Novartis Global Product Portfolio and find information about each pharmaceutical treatment.

  4. Zuellig Pharma Corporation (ZPC) is the exclusive distributor of Novartis products in the Philippines. You may contact ZPC at +63 2 8902 2222. For more information on the availability of Novartis products, call +63 2 7368 7777.

  5. Featured Products of Novartis Healthcare: Afinitor, Certican, Co-Diovan, Desferal, Diovan, Entresto, Exforge, Exforge HCT, Exjade, Femara, Galvus, Galvusme

  6. Use Ruxolitinib (JAKAVI®) as soon as MF patients are eligible to bring the most benefit to their lives 1-4. Patients with MF face increasingly debilitating symptoms as the disease progresses, with symptoms that negatively affect quality of life (QoL) 5-6.

  7. Novartis is responding to COVID-19 with safety of our associates and patients we serve as our main concern. We are contributing to global research efforts, supporting local communities and ensuring stable supply and price of essential medicines.